Harmony Biosciences Holdings ( (HRMY) ) has shared an update.
On April 2, 2025, Harmony Biosciences appointed Ron Philip to its Board of Directors, filling a vacancy left by Jack Bech Nielsen’s resignation in June 2024. Philip, who brings extensive experience from his roles at Orbital Therapeutics and Spark Therapeutics, will serve on the Audit and Nominating and Corporate Governance Committees. His appointment is expected to support Harmony’s growth and pipeline expansion, aligning with the company’s focus on innovative therapies for rare neurological diseases.
More about Harmony Biosciences Holdings
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. Established in 2017 by Paragon Biosciences, LLC, and headquartered in Plymouth Meeting, Pennsylvania, the company is committed to addressing unmet medical needs through novel science and visionary thinking.
YTD Price Performance: -6.60%
Average Trading Volume: 664,109
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.86B
For a thorough assessment of HRMY stock, go to TipRanks’ Stock Analysis page.